Literature DB >> 21815139

High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia.

Anna P Sokolenko1, Aglaya G Iyevleva, Elena V Preobrazhenskaya, Nathalia V Mitiushkina, Svetlana N Abysheva, Evgeny N Suspitsin, Ekatherina Sh Kuligina, Tatiana V Gorodnova, Werner Pfeifer, Alexandr V Togo, Elena A Turkevich, Alexandr O Ivantsov, Dmitry V Voskresenskiy, Georgy D Dolmatov, Elena M Bit-Sava, Dmitry E Matsko, Vladimir F Semiglazov, Iduna Fichtner, Alexey A Larionov, Sergey G Kuznetsov, Antonis C Antoniou, Evgeny N Imyanitov.   

Abstract

The BLM gene belongs to the RecQ helicase family and has been implicated in the maintenance of genomic stability. Its homozygous germline inactivation causes Bloom syndrome, a severe genetic disorder characterized by growth retardation, impaired fertility and highly elevated cancer risk. We hypothesized that BLM is a candidate gene for breast cancer (BC) predisposition. Sequencing of its entire coding region in 95 genetically enriched Russian BC patients identified two heterozygous carriers of the c.1642 C>T (Q548X) mutation. The extended study revealed this allele in 17/1,498 (1.1%) BC cases vs. 2/1,093 (0.2%) healthy women (p = 0.004). There was a suggestion that BLM mutations were more common in patients reporting first-degree family history of BC (6/251 (2.4%) vs. 11/1,247 (0.9%), p = 0.05), early-onset cases (12/762 (1.6%) vs. 5/736 (0.7%), p = 0.14) and women with bilateral appearance of the disease (2/122 (1.6%) vs. 15/1376 (1.1%), p = 0.64). None of the BLM-associated BC exhibited somatic loss of heterozygosity at the BLM gene locus. This study demonstrates that BLM Q548X allele is recurrent in Slavic subjects and may be associated with BC risk.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21815139     DOI: 10.1002/ijc.26342

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec.

Authors:  A L Smith; C Bascuñana; A Hall; A Salman; A Z Andrei; A Volenik; H Rothenmund; D Ferland; D Lamoussenery; A S Kamath; R Amre; D Caglar; Z H Gao; D G Haegert; Y Kanber; R P Michel; G Omeroglu-Altinel; J Asselah; N Bouganim; P Kavan; G Arena; J Barkun; P Chaudhury; S Gallinger; W D Foulkes; A Omeroglu; P Metrakos; G Zogopoulos
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

2.  First Two Cases of Bloom Syndrome in Russia: Lack of Skin Manifestations in a BLM c.1642C>T (p.Q548X) Homozygote as a Likely Cause of Underdiagnosis.

Authors:  Evgeny N Suspitsin; Farida I Sibgatullina; Lydia V Lyazina; Evgeny N Imyanitov
Journal:  Mol Syndromol       Date:  2017-01-17

3.  Analysis of a RECQL splicing mutation, c.1667_1667+3delAGTA, in breast cancer patients and controls from Central Europe.

Authors:  Natalia Bogdanova; Katja Pfeifer; Peter Schürmann; Natalia Antonenkova; Wulf Siggelkow; Hans Christiansen; Peter Hillemanns; Tjoung-Won Park-Simon; Thilo Dörk
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

4.  Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.

Authors:  Evgeny N Suspitsin; Grigory A Yanus; Anna P Sokolenko; Olga S Yatsuk; Olga A Zaitseva; Alexandr A Bessonov; Alexandr O Ivantsov; Valeria A Heinstein; Valery F Klimashevskiy; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2014-01-12       Impact factor: 3.064

5.  Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe.

Authors:  Natalia Bogdanova; Alexandr V Togo; Magdalena Ratajska; Wojtek Kluźniak; Zalina Takhirova; Theresa Tarp; Darya Prokofyeva; Marina Bermisheva; Grigoriy A Yanus; Tatiana V Gorodnova; Anna P Sokolenko; Alina Kuźniacka; Amira Podolak; Maciej Stukan; Dominika Wokołorczyk; Jacek Gronwald; Danuta Vasilevska; Vilius Rudaitis; Ingo B Runnebaum; Matthias Dürst; Tjoung-Won Park-Simon; Peter Hillemanns; Natalia Antonenkova; Elza Khusnutdinova; Janusz Limon; Jan Lubinski; Cezary Cybulski; Evgeny Imyanitov; Thilo Dörk
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

Review 6.  Growing recognition of the role for rare missense substitutions in breast cancer susceptibility.

Authors:  Sean V Tavtigian; Georgia Chenevix-Trench
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

7.  Genome-wide haplotype association study identifies BLM as a risk gene for prostate cancer in Chinese population.

Authors:  Qun Wang; Hongchao Lv; Wenhua Lv; Miao Shi; Mingming Zhang; Meiwei Luan; Hongjie Zhu; Ruijie Zhang; Yongshuai Jiang
Journal:  Tumour Biol       Date:  2014-12-04

Review 8.  Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers.

Authors:  H Wang; L Liang; J-Y Fang; J Xu
Journal:  Oncogene       Date:  2015-08-10       Impact factor: 9.867

9.  Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer.

Authors:  Julie L Boyle; Andrew W Hahn; Ashley L Kapron; Wendy Kohlmann; Samantha E Greenberg; Timothy J Parnell; Craig C Teerlink; Benjamin L Maughan; Bing-Jian Feng; Lisa Cannon-Albright; Neeraj Agarwal; Kathleen A Cooney
Journal:  JCO Precis Oncol       Date:  2020-03-04

10.  Diagnosis of Bloom Syndrome in a Patient with Short Stature, Recurrence of Malignant Lymphoma, and Consanguineous Origin.

Authors:  Jakub Trizuljak; Terezie Petruchová; Ivona Blaháková; Zuzana Vrzalová; Věra Hořínová; Martina Doubková; Jozef Michalka; Jiří Mayer; Šárka Pospíšilová; Michael Doubek
Journal:  Mol Syndromol       Date:  2020-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.